Halozyme Therapeutics Inc (FRA:RV7)
€ 45.9 0.41 (0.9%) Market Cap: 5.88 Bil Enterprise Value: 6.68 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 85/100

Q4 2023 Halozyme Therapeutics Inc Earnings Call Transcript

Feb 20, 2024 / 09:30PM GMT
Release Date Price: €33.23 (-0.48%)
Operator

Hello, and welcome to the Halozyme Fourth Quarter and Fiscal Year 2023 financial and operating results conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. And if you would like to ask a question during this time, simply press star one on your telephone keypad. I will now turn the conference over to Tram Bui. Please go ahead.

Tram Bui
Halozyme Therapeutics, Inc. - Head of IR & Corporate Communications

Thank you, operator. Good afternoon and welcome to our fourth quarter and full year 2023 financial and operating results conference call. And in addition to the press release issued today, after the market closed, you could find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website. Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business and Nicole LaBrosse, our Chief Financial Officer, who will review

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot